Smith & Nephew Dermagraft Will Remain On OPPS Pass-Through List In 2004
This article was originally published in The Gray Sheet
Executive Summary
CMS is granting Smith & Nephew's request that its Dermagraft bio-engineered skin for treating hard-to-heal diabetic foot ulcers be kept on the transitional "pass-through" payment list through 2004, allowing at least two years of pass-through eligibility as a biologic